Tolerability, Safety and Activity of IDN5243, 4 mg Bid Intramuscularly in the Treatment of Low Back Pain. A Prospective, Open Label, Single-center, Uncontrolled Study
Phase of Trial: Phase II
Latest Information Update: 02 Apr 2018
At a glance
- Drugs IDN 5243 (Primary)
- Indications Back pain
- Focus Adverse reactions; Proof of concept
- Sponsors Indena
- 29 Mar 2018 Status changed from not yet recruiting to discontinued.
- 29 Mar 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Mar 2018.
- 29 Mar 2018 Planned initiation date changed from 1 Dec 2016 to 1 Apr 2016.